- Case report
- Open Access
Labetalol infusion for refractory hypertension causing severe hypotension and bradycardia: an issue of patient safety
© Fahed et al; licensee BioMed Central Ltd. 2008
- Received: 18 April 2008
- Accepted: 27 May 2008
- Published: 27 May 2008
Incremental doses of intravenous labetalol are safe and effective and, at times, such therapy may need to be augmented by a continuous infusion of labetalol to control severe hypertension. Continuous infusions of labetalol may exceed the recommended maximum daily dose of 300 mg on occasion. We report a case in which hypertension occurring after an abdominal aortic aneurysm repair, initially responsive to intermittent intravenous beta-blockade, became resistant to this therapy leading to the choice of an intravenous labetalol infusion as the therapeutic option. The labetalol infusion resulted in a profound cardiovascular compromise in this postoperative critically ill patient. While infusions of labetalol have successfully been used, prolonged administration in the intensive care unit requires vigilance and the establishment of a therapeutic rationale/policy for interventions, such as the ready availability of glucagon, β-agonists, phosphodiesterase inhibitors, insulin, and vasopressin when severe cardiovascular depression occurs.
- Abdominal Aortic Aneurysm Repair
- Sodium Nitroprusside
Labetalol is a non-selective β-adrenergic receptor antagonist, and a post-synaptic α-adrenergic receptor antagonist. It is used in the treatment of essential hypertension, renal hypertension, hypertension of pregnancy, pheochromocytoma, and hypertensive crises. It can be administered orally or intravenously. The β/α ratio of antagonism is 7:1 after intravenous administration (a 3:1 ratio exists after oral administration). The drug is lipid-soluble, has a 25% bioavailability, is devoid of active metabolites, and has a half-life of approximately 5.5 hours. Labetalol decreases blood pressure with a limited effect on cardiac output and heart rate at recommended dosages. Its side effects include postural hypotension/dizziness, fatigue, headache, rashes, impotence, urinary retention, gastrointestinal problems, asthma, Raynaud's phenomenon, and heart failure .
Incremental doses of intravenous labetalol have been demonstrated to be safe and effective [2, 3]. A continuous infusion of up to 2 mg/min, or intermittent intravenous (IV) injections of 40 mg or 80 mg following an initial injection have been recommended, to a maximum of 300 mg [2–4]. Long term continuous infusions of labetalol that have exceeded the 300 mg maximum recommendation by the manufacturer have successfully been used to control severe hypertension in medical and trauma patients [5, 6]. However, profound hypotension has also been associated with an infusion dose that nears or exceeds the maximum recommended .
We report a case of labetalol infusion overdose in which profound hypotension and bradycardia occurred in a hypertensive patient after abdominal aortic aneurysm repair. The patient received an infusion that exceeded the manufacturer's recommended cumulative dosage and was rescued with IV glucagon.
A 75 year old 61 kg white female was admitted to the surgical intensive care (SICU) unit after an elective abdominal aortic aneurysm repair. Past medical history included hypertension, renal cell carcinoma, left breast cancer, and peripheral vascular disease. Past surgical history included tonsillectomy, hysterectomy, cholecystectomy, left nephrectomy, left adrenalectomy, and left breast lumpectomy. Her home medications included nitroglycerin, verapamil, and furosemide. She claimed allergies to sulfa, ciprofloxacin, fexofenadine, codeine, cortisone, phenytoin, fluconazole, metoclopramide, penicillin, cisapride, erythromycin, and sertraline.
During the acute event the patient's breathing was controlled in a synchronized intermittent mandatory ventilation mode. The FiO2 was increased from 40% to 100% FiO2 with a resultant ABG of pH 7.45, PaCO2 36 mm Hg, PaO2 312 mm Hg, and HCO3 25 meq/L. The patient's cardiac enzymes were normal and the transthoracic echocardiogram demonstrated normal systolic and diastolic function in the face of left ventricular hypertrophy and moderate mitral regurgitation (which were pre-existing). The electrocardiogram was normal and the chest roentgenogram showed no changes from the morning film.
On post-operative day 24 she received a tracheostomy and on hospital day 45 (post-operative day 44) she was discharged to a long-term facility where she expired 6 months later.
Labetalol infusion rates of 0.5–2 mg/minute have been used without incident to achieve blood pressure control [7–10], including long-term continuous infusions of 20–30 mg/hour IV for 5 days  and 120–180 mg/hour for 14 days  without incident. However, severe refractory hypotension with labetalol may occur, leading to death or severe cardiac dysfunction [11, 12]. The maximum cumulative dose of labetalol used in U.S. clinical trials was 300 mg IV [2–4]. This dosing recommendation may easily be exceeded with a five-hour infusion. The blocking of β-receptors prevents the conversion of adenosine triphosphate to cyclic adenosine monophosphate by the responsible G protein, thereby reducing the amount of cytosolic calcium available for muscular contraction . Besides a reduction in cytosolic calcium, fluctuations in glucose levels are possible with β-blocker overdose, but are rare [14, 15]. Glucagon is normally secreted by the pancreas in response to hypoglycemia, causing the liver to convert stored glycogen into glucose. Glucagon-treated patients may present with the side effects of nausea, vomiting, hypokalemia, and hyperglycemia . As indicated above, our patient had a transient hyperglycemia with the glucagon bolus, but she did not demonstrate nausea, vomiting, or hypokalemia.
For profound β-blocker blockade 0.05–.15 mg/kg of glucagon is administered IV and then followed by 1–5 mg/hr continuous infusion until symptoms subside (this may take as much as 5 labetalol half-lives) . Severe hypotension may occur at the time of administration [11, 17], or several hours after discontinuation [18, 19]. A labetalol infusion leading to β-blocker toxicity has been previously reported once. It occurred in a patient with a subarachnoid hemorrhage and multiple cerebral aneurysms who required hypertension control . The fact that labetalol-induced hypotension may be refractory and can lead to cardiovascular compromise and death is an issue of patient safety [11, 12].
Glucagon has been previously used as a rescue measure in β-blocker overdose [20, 21], as occurred in this case, but evidence of the use of glucagon as the sole rescue drug is limited [21, 22]. In this report, the successful use of glucagon was supported by the use of other drugs. In addition to glucagon, intravenous epinephrine , phosphodiesterase inhibitors [18, 21, 23], insulin , and vasopressin [6, 25] have also been effective. The mechanisms of action for these drugs are as follow: (1) epinephrine binds to β-receptors that are not bound by the β-blocker, thus activating adenyl cyclase through the Gs protein, resulting in the release of calcium via the adenosine triphosphate – adenosine monophosphate (AMP) – protein kinase A pathway ; (2) glucagon acts directly on the Gs protein foregoing the β-receptors entirely ; (3) phosphodiesterase inhibitors prevent the degradation of cyclic AMP ; (4) insulin allows the uptake of carbohydrates (energy), it is anti-inflammatory, and is associated with potassium influx that results in prolonged repolarization allowing calcium channels to remain open for a longer time ; and (5) vasopressin works through the V1A receptor where its activity is mediated by G proteins which stimulate a phosphatidylinositol-calcium secondary messenger system . Furthermore, Jiraj et al have hypothesized that some patients may have significant pharmacologic/physiologic sensitivities to the α1 blocking and/or β2 agonist properties of labetalol, therefore vasopressin may be effective through the V1 receptor [6, 25]. Profound hypotension in the face of vasopressors may indicate a disabled vascular response, or vasoplegia, which may be due to genetic variability .
At our institution vasopressin, phosphodiesterase inhibitors, insulin and vasopressin are more readily available than glucagon. However, except for the use of epinephrine, we did not consider these medications during this clinical event. Additionally, interventions other than a labetalol drip could have been entertained for the control of blood pressure. According to the Vascular Biology Working Group additional options such as a nicardipine infusion, or sodium nitroprusside infusion (with or without β-blockers or angiotensin converting enzyme inhibitors) should be considered in hypertensive urgencies and emergencies .
Figure 1 demonstrates that there was a decrease in systolic, diastolic, and mean blood pressures 1–2 hours beforehand, and, therefore, the more serious drop in blood pressure may have been preventable. Our report is only the second case that we can identify in the literature in which a labetalol infusion has been documented to cause a condition of cardiovascular collapse secondary to β-blocker toxicity.
The medical literature indicates that labetalol is relatively safe to use. However, vigilance is required when it is administered in the form of an intravenous infusion because of the frequency with which the recommended intravenous dose may be exceeded with its prolonged use. We recommend that surgical intensive care units using labetalol infusions to control refractory hypertension have glucagon, epinephrine, insulin, phosphodiesterase inhibitors, and vasopressin readily available for administration.
consent was obtained from the patient's husband for publication.
- MacCarthy EP, Bloomfield SP: Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983, 3: 193-219.PubMedGoogle Scholar
- Wilson DJ, Wallin JD, Vlachakis ND, Freis ED, Vidt DG, Michelson EL, Langford HG, Flamenbaum W, Poland MP: Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. Am J Med. 1983, 75: 95-102. 10.1016/0002-9343(83)90141-9.View ArticlePubMedGoogle Scholar
- Cressman MD, Vidt DG, Gifford RW, Moore WS, Wilson DJ: Intravenous labetalol in the management of severe hypertension and hypertensive emergencies. Am Heart J. 1984, 107: 980-985. 10.1016/0002-8703(84)90838-X.View ArticlePubMedGoogle Scholar
- Papademetriou V, Notargiacomo AV, Khatri IM, Freis ED: Treatment of severe hypertension with intravenous labetalol. Clin Pharmacol Ther. 1982, 32: 431-435.View ArticlePubMedGoogle Scholar
- Vaughb LM, Sudduth , Sahn SA: Long-term infusion of labetalol. Chest. 1991, 99: 522-Google Scholar
- Goldsmith TL, Barker DE, Strodel WE: Prolonged labetalol infusion for management of severe hypertension and tachycardia in a critically ill trauma patient. DICP. 1990, 24 (3): 235-238.PubMedGoogle Scholar
- Jivraj S, Mazer CD, Baker AJ, Choi M, Hare GMT: Case report: Profound hypotension associated with labetalol therapy in a patient with cerebral aneurysms and subarachnoid hemorrhage. Can J Anesth. 2006, 53: 678-683.View ArticlePubMedGoogle Scholar
- Wright TJ, Wilson DJ, Goodman RP, Minisi AJ: Labetalol by continuous infusion in severe hypertension. J Clin Hypertens. 1986, 2: 39-43.PubMedGoogle Scholar
- Gonzalez DG, Ram VS: New approaches for the treatment of hypertensive urgencies and emergencies. Chest. 1988, 93: 193-195.View ArticlePubMedGoogle Scholar
- Lebel M, Langois S, Belleau LJ, Grose JH: Labetalol infusion in hypertensive emergencies. Clin Pharmacol Ther. 1985, 37: 615-618.View ArticlePubMedGoogle Scholar
- Tung A, Sweitzer B, Cutter T: Cardiac Arrest after labetalol and metoclopramide administration in a patient with scleroderma. Anesth Analg. 2002, 95 (6): 1667-1668. 10.1097/00000539-200212000-00035.View ArticlePubMedGoogle Scholar
- Shier JG, Howland MA, Hoffman RS, Nelson LS: Fatality from administration of labetalol and crushed extended-release nefedipine. Ann Pharmacother. 2003, 37: 1420-1423. 10.1345/aph.1D091.View ArticleGoogle Scholar
- Shepherd G: Treatment of poisoning caused by b-adrenergic and calcium-channel blockers. Am J Health Syst Pharm. 2006, 63: 1828-1835. 10.2146/ajhp060041.View ArticlePubMedGoogle Scholar
- Reith DM, Dawson AH, Epid D, Whyte IM, Buckley NA, Sayer GP: Relative toxicity of beta blockers in overdose. J Toxicol Clin Toxicol. 1996, 34: 273-278.View ArticlePubMedGoogle Scholar
- Love JN, Howell JM, Litovitz TL, Klein-Schwartz W: Acute beta blocker overdose: factors associated with the development of cardiovascular morbidity. J Toxicol Clin Toxicol. 2000, 38: 275-381. 10.1081/CLT-100100932.View ArticlePubMedGoogle Scholar
- Peterson CD, Leeder JS, Sterner S: Glucagon therapy for beta-blocker overdose. Drug Intell Clin Pharm. 1984, 18 (5): 394-398.PubMedGoogle Scholar
- Boyd R, Ghosh A: Glucagon for the treatment of symptomatic β blocker overdose. Emerg Med J. 2003, 20: 266-267. 10.1136/emj.20.3.266.PubMed CentralView ArticlePubMedGoogle Scholar
- Kollef MH: Labetalol overdose successfully treated with amrinone and alpha-adrenergic receptor agonists. Chest. 1994, 105: 626-627. 10.1378/chest.105.2.626.View ArticlePubMedGoogle Scholar
- Durant PA, Joucken K: Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy. Br J Anaesth. 1984, 56: 917-920. 10.1093/bja/56.8.917.View ArticlePubMedGoogle Scholar
- Critchley JA, Ungar A: The management of acute poisoning due to beta-adrenoreceptor antagonists. Med Toxicol Adverse Drug Exp. 1989, 4: 32-45.View ArticlePubMedGoogle Scholar
- Baily B: Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review. J Toxicol Clin Toxicol. 2003, 41: 595-602. 10.1081/CLT-120023761.View ArticleGoogle Scholar
- Kerns W, Kline J, Ford MD: Beta-blocker and calcium channel blocker toxicity. Emerg Med Clin North AM. 1994, 12: 365-390.PubMedGoogle Scholar
- Love JN, Leasure JA, Mundt DJ, Janz TG: A comparison of amrinone and glucagons therapy for cardiovascular depression associated with propranolol toxicity in a canine model. J Toxicol Clin Toxicol. 1992, 30: 399-412.View ArticlePubMedGoogle Scholar
- Kerns W, Schroeder D, Williams C, Tomaszewski C, Raymond R: Insulin improves survival in a canine model of acute beta-blocker toxicity. Ann Emerg Med. 1997, 29: 748-757. 10.1016/S0196-0644(97)70196-3.View ArticlePubMedGoogle Scholar
- O'Blenes SB, Roy N, Konstantinov I, Bohn D, Van Arsdell GS: Vasopressin reversal of phenoxybenzamine-induced hypotension after the Norwood procedure. J Thorac Cardiovas Surg. 2002, 123: 1012-1013. 10.1067/mtc.2002.122207.View ArticleGoogle Scholar
- Thibonnier M, Coles P, Thibonnier A, Shoham M: Molecular pharmacology and modeling of the vasopressin receptors. Prog Brain Res. 2002, 139: 179-196.View ArticlePubMedGoogle Scholar
- Bamshad M: Genetic influences on health. Does race matter?. JAMA. 2005, 294: 937-946. 10.1001/jama.294.8.937.View ArticlePubMedGoogle Scholar
- Vascular Biology Working Group. http://vbwg.org
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.